Noriaki Sakuragi

List of Publications by Year
in descending order

34 papers	3,092 citations	394286 19 h-index	414303 32 g-index
36 all docs	36 docs citations	36 times ranked	4747 citing authors

#	Article	IF	Citations
1	Evaluation of partial genotyping with HPV16/18 for triage of HPV positive, cytology negative women in the COMPACT study. Journal of Gynecologic Oncology, 2021, 32, e86.	1.0	5
2	Paracervical and paravaginal tissue dissection in the Okabayashiâ€“Kobayashi radical hysterectomy and nerve-sparing technique. International Journal of Gynecological Cancer, 2021, 31, 145-146.	1.2	1
3	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology, 2021, 39, 3671-3681.	0.8	84
4	Is cytology/HPV coâ€testing for cervical cancer screening useful in Japan?. International Journal of Gynecology and Obstetrics, 2021, , .	1.0	2
5	Nerve-Sparing Radical Hysterectomy Using the Okabayashiâ€“Kobayashi Method. The Surgery Journal, 2021, 07, S48-S56.	0.3	4
6	Oncological Outcomes After Okabayashi-Kobayashi Radical Hysterectomy for Early and Locally Advanced Cervical Cancer. JAMA Network Open, 2020, 3, e204307.	2.8	17
7	Tailored radical hysterectomy for locally advanced cervical cancer. International Journal of Gynecological Cancer, 2020, 30, 1136-1142.	1.2	6
8	Nerve-sparing radical hysterectomy in the precision surgery for cervical cancer. Journal of Gynecologic Oncology, 2020, 31, e49.	1.0	22
9	Implementation of primary HPV testing in Japan. Molecular and Clinical Oncology, 2020, 13, 22.	0.4	5
10	Comparison of human papillomavirus genotyping and cytology triage, <scp>COMPACT</scp> Study: Design, methods and baseline results in 14 642 women. Cancer Science, 2018, 109, 2003-2012.	1.7	14
11	Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4â€“miR-18a pathway in cervical cancer. Oncogene, 2018, 37, 5257-5268.	2.6	95
12	Additive effect of rikkunshito, an herbal medicine, on chemotherapy-induced nausea, vomiting, and anorexia in uterine cervical or corpus cancer patients treated with cisplatin and paclitaxel: results of a randomized phase II study (JORTC KMP-02). Journal of Gynecologic Oncology, 2017, 28, e44.	1.0	43
13	EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis. Oncotarget, 2017, 8, 13509-13520.	0.8	68
14	Isolated tumor cells and micrometastases in regional lymph nodes in stage I to II endometrial cancer. Journal of Gynecologic Oncology, 2016, 27, e1.	1.0	59
15	Suppression of iASPP-dependent aggressiveness in cervical cancer through reversal of methylation silencing of microRNA-124. Scientific Reports, 2016, 6, 35480.	1.6	25
16	MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. Journal of Experimental and Clinical Cancer Research, 2016, 35, 132.	3.5	96
17	Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells. Cancer Research, 2016, 76, 6030-6042.	0.4	142
18	Reactivation of epigenetically silenced miR-124 reverses the epithelial-to-mesenchymal transition and inhibits invasion in endometrial cancer cells via the direct repression of IQGAP1 expression. Oncotarget, 2016, 7, 20260-20270.	0.8	49

#	Article	IF	Citations
19	Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. European Journal of Cancer, 2015, 51, 340-351.	1.3	23
20	Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors. Oncotarget, 2015, 6, 19968-19975.	0.8	23
21	Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection. PLoS ONE, 2014, 9, e94213.	1.1	16
22	Apoptosis and Molecular Targeting Therapy in Cancer. BioMed Research International, 2014, 2014, 1-23.	0.9	885
23	MicroRNA-101 targets EZH2, MCL-1 and FOS to suppress proliferation, invasion and stem cell-like phenotype of aggressive endometrial cancer cells. Oncotarget, 2014, 5, 6049-6062.	0.8	140
24	Ultrastaging of para-aortic lymph nodes in stage IIIC1 endometrial cancer: A preliminary report. Gynecologic Oncology, 2012, 127, 532-537.	0.6	30
25	Risk factors for lower-limb lymphedema after surgery for cervical cancer. International Journal of Clinical Oncology, 2011, 16, 238-243.	1.0	85
26	Risk Factors for Persistent Low Bladder Compliance After Radical Hysterectomy. International Journal of Gynecological Cancer, 2011, 21, 167-172.	1.2	31
27	Laparoscopic retroperitoneal lymphadenectomy for endometrial cancer. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2010, 26, 486-492.	0.0	1
28	Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet, The, 2010, 375, 1165-1172.	6.3	664
29	Clinicopathological analysis of Laparoscopically Removed Appendices of Nineteen Patients with Endometriosis. Japanese Journal of Gynecologic and Obstetric Endoscopy, 2010, 26, 560-564.	0.0	0
30	Prevention of vaginal shortening following radical hysterectomy. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 841-845.	1.1	12
31	Incidence and distribution pattern of pelvic and paraaortic lymph node metastasis in patients with stages IB, IIA, and IIB cervical carcinoma treated with radical hysterectomy. , 1999, 85, 1547-1554.		307
32	Importance of the Transitional Zone between the Cervical Stroma and the Parametrium in the Treatment of Cervical Carcinoma. Journal of Obstetrics and Gynaecology Research, 1997, 23, 111-117.	0.6	7
33	Incidence of ovarian metastasis in patients with cancer of the uterine cervix. Gynecologic Oncology, 1987, 28, 255-261.	0.6	125
34	Serial monitoring of serum estradiol and progesterone levels during the HMG-HCG therapy in six anovulatory women. International Journal of Gynecology and Obstetrics, 1981, 19, 53-56.	1.0	0